Pfizer: FDA gives Xtandi priority review

(CercleFinance.com) - Pfizer announced on Thursday that the US drug regulator, the FDA, has granted priority review to Xtandi, a prostate cancer treatment that the US laboratory is developing in collaboration with the Japanese group Astellas.


The Food and Drug Administration's decision concerns the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)

The drug is already approved in the United States for the treatment of castration-resistant prostate cancer (CRPC).

A target date for the release of the final FDA notice has been set in Q4 this year.


Copyright (c) 2019 CercleFinance.com. All rights reserved.